Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
202
resultados
Última actualización
13/01/2026 [06:49:00]
Resultados 25 a 50 de 202
Resumen de: AU2024303855A1
The present disclosure provides a therapeutic nanodisk, the therapeutic nanodisk comprising: a lipid-binding polypeptide; a lipid bilayer and a therapeutic agent, wherein the therapeutic agent may be of use for treating, preventing a central nervous system disease, disorder, trauma or injury; or as a diagnostic agent for diagnosing a central nervous system disease, disorder, trauma or injury. The lipid bilayer may be 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and the therapeutic agent may be a nucleic acid polymer. Further provided are methods for administration of the therapeutic nanodisk to treat, prevent or diagnose the central nervous system disease, disorder, trauma or injury and uses of such therapeutic nanodisks.
Resumen de: AU2024289812A1
The present invention relates to a composition comprising a solid carrier, a protein disaccharidase or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein disaccharidase or a fragment thereof by embedding the protein disaccharidase or a fragment thereof, and a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group. The present invention also relates to methods of producing said composition.
Resumen de: AU2024290815A1
The present invention relates to a composition comprising a solid carrier, a lipase or a fragment thereof immobilized on the surface of the solid carrier, an agent which interacts with the lid domain of the lipase or a fragment thereof, and a protective layer to protect the lipase or the fragment thereof by embedding the lipase or the fragment thereof, wherein the lipase or a fragment thereof is in the open conformation. The present invention also relates to methods of producing said composition.
Resumen de: AU2024289192A1
The present invention relates to a method of producing a composition, the composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or a fragment thereof by embedding the protein or a fragment thereof, and optionally a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group. The present invention also relates to the composition obtainable by the method.
Resumen de: AU2024285136A1
Compositions are provided that include a lipid nanoparticle (LNP);a self-replicating RNA encoding a gene of interest loaded within the LNP; and an inhibitory nucleic acid, such as a small interfering RNA (siRNA) targeting IFN-α/β receptor l(Ifharl) gene loaded within the LNP, and use of the compositions for generating an immune response.
Resumen de: AU2024280598A1
A siRNA molecule for inhibiting expression of plasminogen activator inhibitor-1 (PAI-1) is disclosed and may have a sense strand and an antisense strand. The sense strand may have at least 80% sequence identity to any one of SEQ ID NOs: 3, 5, 7, and 9. In some embodiments, the antisense strand may have at least 80% sequence identity to any one of SEQ ID NOs: 4, 6, 8, and 10. The sense strand and/or the antisense strand may comprise one or more modified nucleotides. The sense strand and/or the antisense strand may comprise of a ligand. A lipid nanoparticle comprising the siRNA molecule is also disclosed. Methods of using the siRNA molecule or the lipid nanoparticle comprising the siRNA molecule to treat a subject who suffers from at least one PAI-1-associated condition, disease or disorder are also disclosed.
Resumen de: AU2024272060A1
The present disclosure describes improved LNP-based nucleobase editing systems and therapeutics for use in treating hemoglobinopathies, including sickle cell disease and beta-thalassemia. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based nucleobase editing systems and therapeutics to red blood cell progenitor cells, enabling treatment of hemoglobinopathies, in vivo.
Resumen de: AU2024275548A1
The disclosure provides ionizable lipids and lipid nanoparticle (LNP) compositions comprising ionizable lipids, helper lipids, neutral lipids, and PEG lipids useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The LNP compositions disclosed herein are useful in methods of gene editing and methods of delivering a biologically active agent and methods of modifying or cleaving DNA.
Resumen de: AU2024272799A1
The present invention provides a method of producing extracellular vesicles (EVs) comprising incubating or culturing EV producing cells in media. The present invention also provides a population of EVs and compositions comprising the vesicles and methods and uses thereof.
Resumen de: AU2024272694A1
The present disclosure relates to microRNAs (miRs) and extracellular vesicles comprising same and therapeutic uses thereof, for example, in modulating angiogenesis.
Resumen de: MX2025007651A
The present application relates to a polynucleotide molecule that can be used for preventing or treating HPV infection-related diseases, and a pharmaceutical product, a pharmaceutical composition, or an mRNA vaccine comprising said polynucleotide.
Resumen de: WO2026009174A1
The present application discloses formulations comprising polyphenol- loaded phospholipid nanomicelles. The described phospholipid nanomicelles are loaded with resveratrol and/or rutin, which are particularly suitable for the delivery of these polyphenols. The formulations herein described is also suitable for skin diseases or conditions which can be prevented or treated with the administration of resveratrol and/or rutin.
Resumen de: WO2026008881A1
The present invention is in the field of medicine. More specifically, the present invention relates to extracellular vesicles, namely lipid nanoparticles that are conjugated to a biomolecule, namely an antibody or a nanobody, using a click reaction. Such extracellular vesicles can be applied for more effective treatment of diseases, in particular in vivo CAR T therapy, cardiac fibrosis and lysosomal storage diseases (LSD).
Resumen de: WO2026011085A1
This disclosure provides nanoparticle compositions, and use thereof for isolating and measuring proteins, protein degrader action, and cells. The disclosed nanoparticles can be identified by barcodes that reveal the identity of and post translational modifications to the bound protein using image processing techniques described herein.
Resumen de: WO2026010906A1
Provided herein are compositions, methods, and particles that include a peptide that targets placental chondroitin sulfate A (placental CSA), wherein the amino acid sequence of the polypeptide is as set forth in SEQ ID NO: 1 (EDVKDINFDTKEKFLAGLIVSFHEGKC).
Resumen de: WO2026010842A1
The present invention relates to compositions for inducing an immune response against a tumor antigen in a subject, the composition comprising at least one mRNA encoding at least one tumor antigen selected from the group consisting of hTERT, mTERT, and KRASG12D, encapsulated in a lipid nanoparticle.
Resumen de: WO2026010674A1
The present invention discloses a formulation with improved skin permeability. Particularly, the invention is related to a formulation in the form of nanoemulsion comprising at least one lubricant, saponin, oil component, surfactant and at least one pharmaceutical or nutraceutical active ingredient with improved skin permeability.
Resumen de: WO2026010484A1
The present invention relates to multi-layer nanoparticles for nucleic acid delivery, a method for preparing same, a nucleic acid delivery composition comprising same, an antibacterial composition, and a pharmaceutical composition for preventing or treating infectious diseases. The multi-layer nanoparticles for nucleic acid delivery comprise: gold nanoparticles; a polyethyleneimine modified on the surface of the gold nanoparticles; and chitosan applied on the gold nanoparticles modified with the polyethyleneimine. According to the present invention, the introduction of nucleic acids (e.g., ASOs) into target bacterial cells is maximized, and highly efficiently loaded nucleic acids can be effectively delivered into bacteria to maximize the effect of inhibiting target nucleic acids, and thus the present invention can be useful as an antibacterial agent and a gene therapeutic agent.
Resumen de: WO2026010380A1
The present invention relates to a pharmaceutical composition containing lipid nanoparticles that can be used as a drug delivery system (DDS) through blood by loading an mRNA form of a useful anticancer agent or immunomodulator. The lipid nanoparticles (so-called GrAb-LNP) of the present invention do not induce hepatotoxicity in vivo and inhibit the aggregation reaction of proteins present in blood, thereby being able to be effective DDS. That is, the GrAb-LNP of the present invention can act in a target-specific manner on a target tumor or target immune cells by loading mRNA encoding a protein used as an anticancer agent or immunomodulator, thereby allowing for the treatment of cancer or the modulation of immune cells while minimizing damage to normal cells.
Resumen de: WO2026010379A1
The present invention relates to a pharmaceutical composition containing HER2-binding lipid nanoparticles loaded with mRNA encoding p53 protein. The so-called "p53 mRNA-loaded HER-binding lipid nanoparticles" developed in the present invention were verified to deliver p53 mRNA, a tumor inhibitor, which targets highly expressed HER2 in a "human epidermal growth factor receptor 2 (HER2)-positive cancer cell" model, and thus can induce cancer cell death without systemic toxicity.
Resumen de: WO2026009946A1
The purpose of the present invention is to provide: lipid nanoparticles useful as a nucleic acid delivery carrier; and a novel pH-sensitive cationic lipid for producing the lipid nanoparticles. The problem is solved by: a pH-sensitive cationic lipid comprising an asymmetric hydrocarbon chain; and lipid nanoparticles comprising the pH-sensitive cationic lipid as a constituent lipid.
Resumen de: WO2026008008A1
Disclosed herein are a lipid compound based on a biodegradable isocyanide or a biodegradable carboxylic acid terminal group, a preparation method therefor, and a use thereof in the preparation of a lipid compound for gene delivery. Further disclosed herein are a lipid compound for gene delivery, a preparation method therefor, and a use thereof in gene delivery. Further disclosed herein are a liposome and a lipid nanoparticle that comprise the lipid compound for gene delivery, and a gene delivery composition comprising the lipid compound, the liposome, or the lipid nanoparticle. The lipid compound for gene delivery, the liposome, the lipid nanoparticle, and the gene delivery composition herein enable more selective and efficient delivery and release of biomolecules, such as nucleic acids, in immune tissues and organs in vivo.
Resumen de: WO2026010421A1
The present invention relates to a ferritin-protein complex capable of dual targeting and a use thereof. The dual-target ferritin-protein complex of the present invention can selectively deliver a drug only to tumor tissues and cancer cells, thereby increasing the efficacy of the drug.
Resumen de: WO2026007911A1
Disclosed in the present invention are a novel carrier having the functions of inducing ferroptosis and delivering a nucleic acid drug, and use thereof in tumor treatment. The artesunate-protamine conjugate carrier of the present invention conjugates artesunate with protamine by means of an amide bond. The artesunate-protamine conjugate carrier prepared by the present invention has the characteristics of simple components and small toxic and side effects, and can induce ferroptosis of tumor cells. Moreover, said carrier has the function of delivering nucleic acids, and can be used for research in the anti-tumor field.
Nº publicación: WO2026007662A1 08/01/2026
Solicitante:
DSCILAB CO LTD [CN]
\u82CF\u5DDE\u661F\u6838\u8FEA\u8D5B\u751F\u7269\u6280\u672F\u6709\u9650\u516C\u53F8
Resumen de: WO2026007662A1
The present invention relates to a material for local drug delivery and use thereof. Specifically provided is a nanoparticle composition. The nanoparticle composition comprises a cationic lipid, a PEG lipid, and a structural lipid, wherein the lipid component of the PEG lipid is 1.0-5.5 mol%, or a range between any two of the described values. The nanoparticle composition of the present invention is delivered only at the site of administration.
BOPI
Sede Electrónica
